Thorax · 2022
Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Naoi Hyogo, Suzuki Yuzo, Mori Kazutaka, Aono Yuya, Kono Masato, Hasegawa Hirotsugu, Yokomura Koshi, Inoue Yusuke, Hozumi Hironao, Karayama Masato, Furuhashi Kazuki, Enomoto Noriyuki, Fujisawa Tomoyuki, Nakamura Yutaro, Inui Naoki, Nakamura Hidenori, Suda Takafumi
Аннотация
Patients with idiopathic pulmonary fibrosis (IPF) are at a high risk of lung cancer (LC). Antifibrotic therapy slows disease progression and possibly prolongs survival. However, whether antifibrotic therapy affects LC development in patients with IPF remains unknown. This multicentre retrospective study evaluated 345 patients with IPF. The incidence and prevalence of LC were significantly lower in patients with IPF receiving antifibrotic therapy than those not receiving. Subsequently, LC-related mortality was significantly lower in patients with IPF receiving antifibrotic therapy. These results suggest that antifibrotic therapy was possibly associated with a reduced risk of LC development in patients with IPF, which may be partly associated with its survival benefit.